Article Details
Retrieved on: 2025-02-04 14:18:34
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA approval of Supernus Pharmaceuticals’ ONAPGO, a subcutaneous apomorphine infusion device for Parkinson’s disease. Tags and key concepts relate as this device delivers apomorphine, a dopamine agonist, targeting the U.S. Parkinson's market.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here